Literature DB >> 32859655

The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility.

Natasha B Hunter1,2, Mark R Kilgore3, Nancy E Davidson4,2.   

Abstract

Tumor data from the ABCSG 5 trial of chemotherapy versus endocrine therapy for premenopausal ER+ breast cancer supports molecular subtyping by Ki-67 IHC as a prognostic marker. But while this tissue was handled uniformly, Ki-67 testing overall is unstandardized, complicating clinical utility. Increasing potential biomarkers herald more challenges in biomarker validation.See related article by Bago-Horvath et al., p. 5682. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32859655      PMCID： PMC8791049          DOI： 10.1158/1078-0432.CCR-20-2451

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast.

Authors:  Patrick L Fitzgibbons; Deborah A Dillon; Randa Alsabeh; Michael A Berman; Daniel F Hayes; David G Hicks; Kevin S Hughes; Sharon Nofech-Mozes
Journal:  Arch Pathol Lab Med       Date:  2013-11-15       Impact factor: 5.534

2.  Breast cancer prognostic factors: evaluation guidelines.

Authors:  W L McGuire
Journal:  J Natl Cancer Inst       Date:  1991-02-06       Impact factor: 13.506

Review 3.  Ki67 in breast cancer: prognostic and predictive potential.

Authors:  Rinat Yerushalmi; Ryan Woods; Peter M Ravdin; Malcolm M Hayes; Karen A Gelmon
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

4.  Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Authors:  Joseph A Sparano; Robert J Gray; Della F Makower; Kathleen I Pritchard; Kathy S Albain; Daniel F Hayes; Charles E Geyer; Elizabeth C Dees; Matthew P Goetz; John A Olson; Tracy Lively; Sunil S Badve; Thomas J Saphner; Lynne I Wagner; Timothy J Whelan; Matthew J Ellis; Soonmyung Paik; William C Wood; Peter M Ravdin; Maccon M Keane; Henry L Gomez Moreno; Pavan S Reddy; Timothy F Goggins; Ingrid A Mayer; Adam M Brufsky; Deborah L Toppmeyer; Virginia G Kaklamani; Jeffrey L Berenberg; Jeffrey Abrams; George W Sledge
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

5.  Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5.

Authors:  Zsuzsanna Bago-Horvath; Margaretha Rudas; Christian F Singer; Richard Greil; Marija Balic; Sigurd F Lax; Werner Kwasny; Wolfgang Hulla; Michael Gnant; Martin Filipits
Journal:  Clin Cancer Res       Date:  2020-06-16       Impact factor: 12.531
  5 in total
  2 in total

1.  Preoperative ultrasound radiomics analysis for expression of multiple molecular biomarkers in mass type of breast ductal carcinoma in situ.

Authors:  Linyong Wu; Yujia Zhao; Peng Lin; Hui Qin; Yichen Liu; Da Wan; Xin Li; Yun He; Hong Yang
Journal:  BMC Med Imaging       Date:  2021-05-17       Impact factor: 1.930

2.  HAUS5 Is A Potential Prognostic Biomarker With Functional Significance in Breast Cancer.

Authors:  Zhijian Huang; Jiasheng Yang; Wenjing Qiu; Jing Huang; Zhirong Chen; Yuanyuan Han; Changsheng Ye
Journal:  Front Oncol       Date:  2022-02-25       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.